Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review
Abstract Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emph...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Series: | Annals of Clinical and Translational Neurology |
| Online Access: | https://doi.org/10.1002/acn3.52017 |
| _version_ | 1797203086619443200 |
|---|---|
| author | Patricia K. Coyle Mark S. Freedman Bruce A. Cohen Bruce A. C. Cree Clyde E. Markowitz |
| author_facet | Patricia K. Coyle Mark S. Freedman Bruce A. Cohen Bruce A. C. Cree Clyde E. Markowitz |
| author_sort | Patricia K. Coyle |
| collection | DOAJ |
| description | Abstract Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emphasis on similarities and differences. Efficacy data from the pivotal clinical trials are generally similar for the four agents. However, because no head‐to‐head clinical studies were conducted, direct efficacy comparisons cannot be made. Based on the adverse event profile of S1P receptor modulators, continued and regular monitoring of patients during treatment will be instructive. Notably, the authors recommend paying attention to the cardiac monitoring guidelines for these drugs, and when indicated screening for macular edema and cutaneous malignancies before starting treatment. To obtain the best outcome, clinicians should choose the drug based on disease type, history, and concomitant medications for each patient. Real‐world data should help to determine whether there are meaningful differences in efficacy or side effects between these agents. |
| first_indexed | 2024-04-24T08:13:45Z |
| format | Article |
| id | doaj.art-3b35a014dd2647ea854c658e2d16a68d |
| institution | Directory Open Access Journal |
| issn | 2328-9503 |
| language | English |
| last_indexed | 2024-04-24T08:13:45Z |
| publishDate | 2024-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Clinical and Translational Neurology |
| spelling | doaj.art-3b35a014dd2647ea854c658e2d16a68d2024-04-17T04:36:58ZengWileyAnnals of Clinical and Translational Neurology2328-95032024-04-0111484285510.1002/acn3.52017Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical reviewPatricia K. Coyle0Mark S. Freedman1Bruce A. Cohen2Bruce A. C. Cree3Clyde E. Markowitz4Department of Neurology, Stony Brook Renaissance School of Medicine Stony Brook University Stony Brook New York USAUniversity of Ottawa Department of Medicine and the Ottawa Hospital Research Institute Ottawa Ontario CanadaDepartment of Neurology Northwestern University, Feinberg School of Medicine Chicago Illinois USAWeill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco California USADepartment of Neurology, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USAAbstract Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emphasis on similarities and differences. Efficacy data from the pivotal clinical trials are generally similar for the four agents. However, because no head‐to‐head clinical studies were conducted, direct efficacy comparisons cannot be made. Based on the adverse event profile of S1P receptor modulators, continued and regular monitoring of patients during treatment will be instructive. Notably, the authors recommend paying attention to the cardiac monitoring guidelines for these drugs, and when indicated screening for macular edema and cutaneous malignancies before starting treatment. To obtain the best outcome, clinicians should choose the drug based on disease type, history, and concomitant medications for each patient. Real‐world data should help to determine whether there are meaningful differences in efficacy or side effects between these agents.https://doi.org/10.1002/acn3.52017 |
| spellingShingle | Patricia K. Coyle Mark S. Freedman Bruce A. Cohen Bruce A. C. Cree Clyde E. Markowitz Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review Annals of Clinical and Translational Neurology |
| title | Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review |
| title_full | Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review |
| title_fullStr | Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review |
| title_full_unstemmed | Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review |
| title_short | Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review |
| title_sort | sphingosine 1 phosphate receptor modulators in multiple sclerosis treatment a practical review |
| url | https://doi.org/10.1002/acn3.52017 |
| work_keys_str_mv | AT patriciakcoyle sphingosine1phosphatereceptormodulatorsinmultiplesclerosistreatmentapracticalreview AT marksfreedman sphingosine1phosphatereceptormodulatorsinmultiplesclerosistreatmentapracticalreview AT bruceacohen sphingosine1phosphatereceptormodulatorsinmultiplesclerosistreatmentapracticalreview AT bruceaccree sphingosine1phosphatereceptormodulatorsinmultiplesclerosistreatmentapracticalreview AT clydeemarkowitz sphingosine1phosphatereceptormodulatorsinmultiplesclerosistreatmentapracticalreview |